A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Study identifier:CD-ON-MEDI-551-1088

ClinicalTrials.gov identifier:NCT01453205

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL

Medical condition

Diffuse Large B-Cell Lymphoma

Phase

Phase 2

Healthy volunteers

No

Study drug

MEDI-551 2 mg/kg, Rituximab, ICE, DHAP, MEDI-551 4 mg/kg

Sex

All

Actual Enrollment

187

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 27 Feb 2012
Primary Completion Date: 11 Jul 2016
Study Completion Date: 11 Jul 2016

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2018 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria